Digg
Del.icio.us
Yahoo
Google
Newsvine
WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
SCRI in the News
February 09, 2012
|
OncLive | 02/08/12 15:39 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Howard A. "Skip" Burris, III, MD, chief medical officer and executive director, Drug Development Program, Sarah Cannon Research Institute in Nashville, Tennessee, discusses the need for patient population stratification in breast cancer trials.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Now Available: Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2012 |
|
Live-PR (EN) | 02/01/12 09:17 |
|
(live-PR.com) - GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2011" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. |
|
4-Traders | 01/30/12 16:35 |
|
Array BioPharma Inc. (NASDAQ: ARRY) today reported financial results for the second quarter of fiscal 2012. Array reported revenue of $23.2 million for the second quarter of fiscal 2012, compared to revenue of $16. |
|
Cmr Nashville Radio | 01/31/12 02:26 |
|
Organization Launches “Minnie Moments” Campaign for Clients, Survivors, Caregivers and and Fans to Share Their Stories and Celebrate Minnie’s Legacy The Minnie Pearl Cancer Foundation (MPCF), a national nonprofit organization offering FREE and compassionate support, education and one-on-one guidance |
|
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2012 |
|
Pharmiweb | 01/31/12 03:01 |
|
Array BioPharma Inc. (NASDAQ: ARRY) today reported financial results for the second quarter of fiscal 2012. Array reported revenue of $23.2 million for the second quarter of fiscal 2012, compared to revenue of $16. |
|
Biotech Intelligence | 01/30/12 13:31 |
|
WINNIPEG, Manitoba – (January 30, 2012) Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJ.PK) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled “Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention” (SAVI-PCI). |
|
Live-PR (EN) | 01/30/12 09:38 |
|
(live-PR.com) - WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Co |
|
Stockwatch | 01/30/12 09:07 |
(live-PR.com) - WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Marketwire - Jan. 30, 2012
WINNIPEG, MANITOBA -- (MARKET WIRE) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
News from globeandmail.com
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
Monday, January 30, 2012
WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Published: January 30, 2012
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
Mon Jan 30, 2012 8:30am EST
WINNIPEG, MANITOBA, Jan 30 (MARKET WIRE) --
Medicure Inc. ("Medicure" or the "Company") (TSX
VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new
clinical trial of AGGRASTAT(R) (tirofiban HCl) entitled "Shortened
Aggrastat Versus Integrilin in Percutaneous Coronary Intervention"
(SAVI-PCI).
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI3
by Marketwire
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT(R) (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
WINNIPEG, MANITOBA, Jan 30, 2012 (MARKETWIRE via COMTEX) -- Medicure Inc. ("Medicure" or the "Company") /quotes/zigman/4513555 CA:MPH +100.00% (pinksheets:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT(R) (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Monday, January 30, 2012 8:30 AM
WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH.V - News)(PINKSHEETS:MCUJ.PK - News) is pleased to announce its plans for a new clinical trial of AGGRASTAT(R) (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
@ Marketwire 20122012-01-30 14:34:55 -
WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
Press Release: Medicure Inc. –
WINNIPEG, MANITOBA--(Marketwire -01/30/12)- Medicure Inc. ("Medicure" or the "Company") (TSX-V: MPH.V - News)(Pinksheets: MCUJ.PK - News) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
January 30, 2012 8:30 AM EST
WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT(R) (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI
WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ)
is pleased to announce its plans for a new clinical trial of AGGRASTAT(R)
(tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous
Coronary Intervention" (SAVI-PCI).
|
WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
WINNIPEG, MANITOBA -- (Marketwire) -- 01/30/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJ) is pleased to announce its plans for a new clinical trial of AGGRASTAT® (tirofiban HCl) entitled
Medicure to run 600-patient clinical trial on Aggrastat
2012-01-30 09:07 ET - News Release
Dr. Steven Manoukian reports
MEDICURE ANNOUNCES AGGRASTAT CLINICAL TRIAL: SAVI-PCI
Medicure Inc. has released its plans for a new clinical trial of AGGRASTAT (tirofiban HCl) entitled "Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention" (SAVI-PCI).
|
JTCC brings leading experts to present 2011 San Antonio Breast Cancer Symposium research |
|
PhysOrg.com | 01/26/12 13:43 |
|
(January 26, 2012) – Mark your calendars, the Breast Cancer Division of the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will recap and explain research from the 2011 San Antonio Breast Cancer Symposium on Friday, February 17. |
|
Nashville Business Journal | 01/25/12 09:24 |
|
Congratulations are in order for the Nashville Business Journal’s Forty Under 40 class of 2012. The following 40 winners, first named during a reveal party Tuesday night at Nashville City Club , were deemed to be making a difference in their companies and community by a panel of judges. |
|
Reuters Press Release News Headlines | 01/24/12 12:21 |
|
bioMérieux - 2011 Business Review Regulatory News: Sales: Up 6.5% at constant exchange rates Including 4.1% organic growth Double-digit growth* in 11 countries Including: India** (up 28%), China (up 20%), Brazil (up 18%) and Turkey (up 18%) Sustained momentum in clinical microbiology, up 8. |
|
Ad Hoc News | 01/24/12 12:00 |
|
Regulatory News: |
|
...of VITEK® 2 installations. A clinical study led by the Sarah Cannon Research Institute demonstrated the utility of CancerTYPE ID®, a molecular... |
|
4-Traders | 01/24/12 12:05 |
|
Regulatory News: Sales: Up 6.5% at constant exchange rates Including 4.1% organic growth Double-digit growth* in 11 countries Including: India** (up 28%), China (up 20%), Brazil (up 18%) and Turkey (up 18%) Sustained momentum in clinical microbiology, up 8. |
|
Barrons | 01/24/12 12:11 |
|||
|
-- Sales: -- Up 6.5% at constant exchange rates -- Including 4.1% organic growth -- Double-digit growth* in 11 countries -- Including: India** (up 28%), China (up 20%), Brazil (up 18%) and Turkey (up 18%) -- Sustained momentum in clinical microbiology, up 8. |
|||
|
Sarah Cannon Research Institute to Present at ASCO Gastrointestinal... |
|
Finwin | 01/20/12 10:40 |
|
Business Editors/Health/Medical Writers NASHVILLE, Tenn.--(BUSINESS WIRE)--Jan. 20, 2012--Sarah Cannon Research Institute (SCRI) physicians authored four abstracts accepted for presentation at the ASCO 2012 Gastrointestinal Cancers Symposium, which runs from Jan. |
|
Sarah Cannon Research Institute to Present at ASCO Gastrointestinal Cancers Symposium |
|
Pharmiweb | 01/20/12 11:01 |
|
Sarah Cannon Research Institute (SCRI) physicians authored four abstracts accepted for presentation at the ASCO 2012 Gastrointestinal Cancers Symposium, which runs from Jan. |
|
Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent |
|
PR-Canada.net | 01/21/12 14:20 |
|
Press Release Point | 01/18/12 18:29 |
|
Niiki Pharma announced today that it has completed the dose escalation portion of the Phase I clinical trial of its lead product, NKP-1339, a first-in-class small molecule that down-regulates GRP78, a key tumor survival and anti-apoptosis factor. |
|
Niiki Pharma Announces Phase I Dose Escalation Complete for First-in-Man Anti-Cancer Agent NKP-1339 |
|
The Open Press | 01/19/12 00:48 |
|
Hoboken, NJ and Philadelphia, PA (OPENPRESS) January 19, 2012 -- Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial of its lead product, NKP-1339. |
|
|
|
Pharmalive.com | 01/17/12 17:10 |
|
PRNewswire/ -- Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial of its lead product, NKP-1339. |
|
StockRants | 01/17/12 14:26 |
|
Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339 Trial Demonstrates Favorable Safety Profile with Anti-Tumor Activity PR Newswire |
|
Recently released market study: Lung Cancer Global Clinical Trials Review, H2, 2011 |
|
Live-PR (EN) | 01/11/12 21:57 |
|
(live-PR.com) - GlobalData's clinical trial report, "Lung Cancer Global Clinical Trials Review, H2, 2011" provides data on the Lung Cancer clinical trial scenario. |
New Pharmaceuticals market report from GlobalData: "Lung Cancer Global Clinical Trials Review, H2, 2011"
Fast Market Research recommends "Kidney Cancer Global Clinical Trials Review, H2, 2011" from GlobalData, now available
The Multiple Myeloma Research Consortium (MMRC) today announced that it opened more multiple myeloma clinical trials at its member institutions during 2011 than any other year since the Consortium was founded in 2004.
NORWALK, Conn.--(BUSINESS WIRE)-- The Multiple Myeloma Research Consortium (MMRC) today announced that it opened more multiple myeloma clinical trials at its member institutions during 2011 than any other year since the Consortium was founded in 2004.
The Multiple Myeloma Research Consortium (MMRC) today announced that it has awarded Washington University School of Medicine in St. Louis and Ravi Vij, MD, with the 2011 MMRC Center of the Year Award. The MMRC Center of the Year Award recognizes the outstanding efforts of an MMRC Member Institution
NORWALK, Conn. --(Business Wire)-- The Multiple Myeloma Research Foundation (MMRF) today announced that four leading cancer centers are enrolling patients as part of the landmark 1,000-patient study designed to characterize the genetic variation in multiple myeloma
Multiple Myeloma Research Consortium (MMRC) Presents New Data Affirming Success in Accelerating Drug Development Timelines Posted December 18, 2011 Oral Presentation at American Society of Hematology (ASH) Annual Meeting Highlights Model to Dramatically Speed Clinical Trial Startup, Accrual,
http://www.themmrf.orgMultimedia Gallery URL NORWALK, Conn.--(BUSINESS WIRE)-- The Multiple Myeloma Research Consortium (MMRC) today presented compelling new results highlighting its success in accelerating the completion of clinical trials and the development of treatments for multiple myeloma
Business Editors/Health/Medical Writers NORWALK, Conn.--(BUSINESS WIRE)--Dec. 13, 2011--The Multiple Myeloma Research Consortium (MMRC) today presented compelling new results highlighting its success in accelerating the completion of clinical trials and the development of treatments for multiple
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported Phase I and Phase I/II results from three studies evaluating the safety, tolerability and dosing of MLN9708, the first oral proteasome inhibitor in clinical trials.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported Phase I and Phase I/II results from three studies evaluating the safety, tolerability and dosing of MLN9708, the first oral proteasome
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported Phase I and Phase I/II results from three studies evaluating the safety, tolerability and dosing of MLN9708, the first oral proteasome inhibitor in clinical trials.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported Phase I and Phase I/II results from three studies evaluating the safety, tolerability and dosing of MLN9708, the first oral proteasome inhibitor in clinical trials.
A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.
PCI-32765 applies molecularly aimed attack to disease usually treated with chemotherapy combinations SAN DIEGO — A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investig
Source: University of Texas M. D. Anderson Cancer Center
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.
{The Medical News via BioPortfolio} Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.
Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important blood cancer trials during the 53rdAnnual Meeting of the American Society of Hematology (ASH) in San Diego December 10-13.
ENP Newswire - 09 December 2011 Release date- 08122011 - In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson
In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer Center.
Source: University of Texas M. D. Anderson Cancer Center
WALTHAM, Mass., Dec. 7, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. announced today that, with a 23-month patient follow up of ENCORE 301, a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 patients with locally recurrent
Main Category: Breast Cancer Article Date: 08 Dec 2011 In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Canc
--Seven-month survival advantage for exemestane plus entinostat treated patients-- --Data presented at San Antonio Breast Cancer Symposium--
Share With Friends Newswise - San Antonio, TX - In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer
Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway.
WALTHAM, Mass., Dec. 7, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. announced today that, with a 23-month patient follow up of ENCORE 301, a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 patients with locally recurrent
Survival Benefit With Syndax Pharmaceuticals’ Entinostat Maintained in Women with Advanced Breast Cancer –Seven-month survival advantage for exemestane plus entinostat treated patients– –Data presented at San Antonio Breast Cancer Symposium– PR Newswire WALTHAM, Mass.
In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer Center.
Dec 07, 2011 (Close-Up Media via COMTEX) -- The Multiple Myeloma Research Consortium (MMRC) announced that it has expanded its clinical research network to include the Barbara Ann Karmanos Cancer Institute in Detroit, Mich.
The Multiple Myeloma Research Consortium (MMRC) today announced that eight abstracts from its clinical collaborations with academia and industry have been accepted for oral and poster presentations at this year's American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2011
The Multiple Myeloma Research Consortium (MMRC) today announced that eight abstracts from its clinical collaborations with academia and industry have been accepted for oral and poster presentations at this year's American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2011
Denise A. Yardley, M.D., senior investigator, breast cancer research for Sarah Cannon Research Institute (SCRI) serves as primary or co-author of ten breast cancer clinical trial abstracts that have been accepted for presentation during the 34th Annual San Antonio Breast Cancer Symposium (SABCS)
MacroGenics, Servier enter pact to develop and commercialize novel anti-cancer drug
Pharmabiz | 12/05/11 03:50
A privately held biotechnology company that develops next generation antibody therapeutics, MacroGenics, Inc., and France’s largest privately-held pharmaceutical company, Servier, entered into an option for a license agreement for the development and commercialization of MGA271, MacroGenics’...
Pharmiweb | 12/03/11 03:08
The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include the Barbara Ann Karmanos Cancer Institute in Detroit, Mich.
Multiple Myeloma Research Consortium (MMRC) Welcomes the Barbara An...
Finwin | 12/02/11 18:20
Business Editors/Health/Medical Writers NORWALK, Conn.--(BUSINESS WIRE)--Dec. 02, 2011--The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include the Barbara Ann Karmanos Cancer Institute in Detroit, Mich.
Ad Hoc News | 12/02/11 18:02
The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include the Barbara Ann Karmanos Cancer Institute in Detroit, Mich. Following a rigorous evaluation, this NCI-designated comprehensive cancer center joins the existing MMRC member in
Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences
CBS5 - KPHO | 12/01/11 20:18
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
CBS5 - KPHO | 12/01/11 20:18
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
BioSpace | 12/01/11 15:00
WALTHAM, Mass., Dec. 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that multiple data presentations from phase 2 clinical trials with entinostat in combination and as a single agent will be made at upcoming scientific conferences.
MacroGenics And Servier Enter Development And Commercialization Agreement For Novel Anti-Cancer Drug
Biocompare | 12/02/11 01:11
Source: MacroGenics, Inc.
...has been completed. Clinical investigators include Dr. Howard Burris at Sarah Cannon Research Institute, Dr. Roger Cohen at Hospital of the University...
Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences
The Salinas Californian - mediawebsite.net | 12/01/11 15:45
--Updated data in advanced breast cancer to be presented at San Antonio Breast Cancer Symposium-- --Single-agent data in Hodgkin's lymphoma to be presented at American Society of Hematology Annual Meeting and Exposition...
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
The Salinas Californian - mediawebsite.net | 12/01/11 15:16
- MGA271 is a therapeutic monoclonal antibody that recognizes B7-H3, a member of the B7 family of immune regulators, that is over-expressed on a wide variety of solid tumors - MacroGenics retains full program rights in North America, Japan, Korea and India...
Array BioPharma to Host Analyst and Investor Day Featuring Distinguished Clinical Investigators
News Blaze | 12/01/11 11:24
Share With Friends BOULDER, Colo. - (BUSINESS WIRE) - Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will host an Analyst and Investor Day on Friday, December 16, 2011
4-Traders | 12/01/11 10:05
Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will host an Analyst and Investor Day on Friday, December 16, 2011, from 8:30 a.m. to 11:30 a.m...
Virtual Press Office | 12/01/11 09:42
WALTHAM, Mass., Dec. 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that multiple data presentations from phase 2 clinical trials with entinostat in combination and as a single agent will be made at upcoming scientific conferences...
Multiple Data Presentations on Syndax Pharmaceutical’s Entinostat at Upcoming Scientific Conferences
StockRants | 12/01/11 08:55
Multiple Data Presentations on Syndax Pharmaceutical’s Entinostat at Upcoming Scientific Conferences –Updated data in advanced breast cancer to be presented at San Antonio Breast Cancer Symposium– –Single-agent data in Hodgkin’s lymphoma to be presented at American Society of Hematology Annual Meeting...
Multiple Data Presentations On Syndax Pharmaceutical's Entinostat At Upcoming Scientific Conferences
The Street | 12/01/11 08:46
WALTHAM, Mass., Dec. 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that multiple data presentations from phase 2 clinical trials with entinostat in combination and as a single agent will be made at upcoming scientific conferences...
Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming
Finwin | 12/01/11 08:30
Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences--Updated data in advanced breast cancer to be presented at San Antonio Breast Cancer Symposium----Single-agent data in Hodgkin's lymphoma to be presented at American Society of Hematology Annual Meeting...
MacroGenics, Inc. Inks Pharma Deal With Servier Worth Up to $450 Million
BioSpace | 12/01/11 07:50
ROCKVILLE, Maryland and SURESNES, France, Dec. 1, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an op...
Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences
BioPortfolio | 11/30/11 22:45
{PR Newswire via BioPortfolio} WALTHAM, Mass., Dec. 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that multiple data presentations from phase 2 clinical trials with entinostat in combination and as a single agent will be made at...
Array BioPharma to Host Analyst and Investor Day Featuring Distinguished Clinical Investigators
Investor Point | 11/30/11 18:00
Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will host an Analyst and Investor Day on Friday, December 16, 2011, from 8:30 a.m. to 11:30 a.
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
Investor Point | 11/30/11 15:00
- MGA271 is a therapeutic monoclonal antibody that recognizes B7-H3, a member of the B7 family of immune regulators, that is over-expressed on a wide variety of solid tumors - MacroGenics retains full program rights in North America, Japan, Korea and India -
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
KTIV News | 12/01/11 07:50
/PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an option for a license agreement for the development and co...
MacroGenics and Servier Enter Development and Commercialization Agreement for
Finwin | 12/01/11 07:00
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug- MGA271 is a therapeutic monoclonal antibody that recognizes B7-H3, a member of the B7 family of immune regulators, that is over-expressed on a wide variety of solid tumors- MacroGenics retains full...
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
BioPortfolio | 11/30/11 21:15
{PR Newswire via BioPortfolio} ROCKVILLE, Maryland and SURESNES, France, Dec. 1, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today today...
Clinical Lab Products | 11/29/11 19:26
-Oncotype DX DCIS Results to be Highlighted in SABCS Press Briefing on December 7, 7:30 AM CST-...
Journal Of Clinical Oncology | 11/29/11 18:33
Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA; David R. Spigel, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; David Chen, Kai Habben, Lian Liu, and Carrie M...
Medcompare | 11/29/11 08:01
Source: Genomic Health, Inc. REDWOOD CITY, Calif., Nov. 29, 2011 /PRNewswire/ -- Genomic Health, Inc. today announced that the company will present results from sixteen studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 6-10, 2011 at the Henry B...
Pharmalive.com | 11/29/11 11:35
PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from sixteen studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 6-10, 2011 at the Henry B...
4-Traders | 11/29/11 08:36
REDWOOD CITY, Calif., Nov. 29, 2011(Nasdaq: GHDX) today announced that the company will present results from sixteen studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 6-10, 2011at the Henry B...
Genomic Health Announces Presentation of
Virtual Press Office | 11/29/11 08:00
Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium -Oncotype DX DCIS Results to be Highlighted in SABCS Press Briefing on December 7, 7:30 AM CST- REDWOOD CITY, Calif...
Our News
View All News-
SCRI in the News
February 09, 2012
-
NBJ announces the Forty Under 40 class of 2012
January 25, 2012
Congratulations are in order for the Nashville Business Journal’s Forty Under 40 class of 2012. The following 40 winners, first named during a reveal party Tuesday night at Nashville City Club , were deemed to be making a difference in their companies and community by a panel of judges.
-
World-class care right here at home
January 23, 2012
When it arrives, a diagnosis of cancer can be among the most devastating of news to a patient and their families. For local residents, the course of treatment has often meant weekly trips to nearby Murfreesboro or Nashville for chemotherapy.